Introduction: Pharmaceutical companies have boosted vaccine production following the global COVID-19 pandemic. In Côte d’Ivoire, the first vaccination campaign with the AstraZeneca vaccine began on March 1, 2021...Introduction: Pharmaceutical companies have boosted vaccine production following the global COVID-19 pandemic. In Côte d’Ivoire, the first vaccination campaign with the AstraZeneca vaccine began on March 1, 2021, as part of the Covax program. Despite the positive benefit/risk balance, the adverse effects of vaccination should not be minimized. Objective: To identify adverse events of AstraZeneca’s COVID-19 vaccination for better management. Materials and Methods: This is a case of a 57-year-old obese (BMI = 39 kg/m2) female health care worker who experienced adverse events in March 2021 after the second dose of AstraZeneca vaccine administered 4 weeks apart. These were subject to mandatory case reporting. Results: Major post-vaccination events occurred in a noisy systemic picture with parameters showing significant disturbances. Biological surveillance remains costly and makes the accountability of the vaccine complex. Conclusion: Vaccination remains the ultimate weapon in the fight against endemic diseases but should not overshadow the reporting of adverse events.展开更多
AstraZeneca公司的CEO D Brennan在一次商务战略会议上指出，尽管公司销路最好的产品面临通用名药的竞争，但他对公司的中近期前景表示乐观。他概述了该集团加强新产品研发的战略，包含3个基本元素，即提高企业内发现和开发努力的产率...AstraZeneca公司的CEO D Brennan在一次商务战略会议上指出，尽管公司销路最好的产品面临通用名药的竞争，但他对公司的中近期前景表示乐观。他概述了该集团加强新产品研发的战略，包含3个基本元素，即提高企业内发现和开发努力的产率、大力寻求有苗头的外源产品和技术，和以收购Cambridge Antibady公司（CAT）为契机，在生物治疗药的研发方面确立国际地位，以作为该公司小分子研发能力的补充。展开更多
文摘Introduction: Pharmaceutical companies have boosted vaccine production following the global COVID-19 pandemic. In Côte d’Ivoire, the first vaccination campaign with the AstraZeneca vaccine began on March 1, 2021, as part of the Covax program. Despite the positive benefit/risk balance, the adverse effects of vaccination should not be minimized. Objective: To identify adverse events of AstraZeneca’s COVID-19 vaccination for better management. Materials and Methods: This is a case of a 57-year-old obese (BMI = 39 kg/m2) female health care worker who experienced adverse events in March 2021 after the second dose of AstraZeneca vaccine administered 4 weeks apart. These were subject to mandatory case reporting. Results: Major post-vaccination events occurred in a noisy systemic picture with parameters showing significant disturbances. Biological surveillance remains costly and makes the accountability of the vaccine complex. Conclusion: Vaccination remains the ultimate weapon in the fight against endemic diseases but should not overshadow the reporting of adverse events.
文摘AstraZeneca公司的CEO D Brennan在一次商务战略会议上指出，尽管公司销路最好的产品面临通用名药的竞争，但他对公司的中近期前景表示乐观。他概述了该集团加强新产品研发的战略，包含3个基本元素，即提高企业内发现和开发努力的产率、大力寻求有苗头的外源产品和技术，和以收购Cambridge Antibady公司（CAT）为契机，在生物治疗药的研发方面确立国际地位，以作为该公司小分子研发能力的补充。
